Table 5.
Relation between liver fatty acid-binding protein expression and other immunohistochemical markers n (%)
| Immunostaining |
Tumor size ≤ 2 cm |
P value |
Tumor size > 2 cm |
P value |
Total |
P value | |||
| L-FABP negative n = 11 | L-FABP positive n = 74 | L-FABP negative n = 5 | L-FABP positive n = 56 | L-FABP negative n = 16 | L-FABP positive n = 130 | ||||
| CK 7 | 0.430 | 0.515 | 0.512 | ||||||
| Negative | 4 (36.4) | 33 (44.6) | 3 (60.0) | 28 (50.0) | 7 (43.8) | 61 (46.9) | |||
| Positive | 7 (63.6) | 41 (55.4) | 2 (40.0) | 28 (50.0) | 9 (56.2) | 69 (53.1) | |||
| CK 19 | 0.423 | 0.703 | 0.301 | ||||||
| Negative | 11 (100) | 68 (91.9) | 5 (100) | 52 (92.9) | 16 (100) | 120 (92.3) | |||
| Positive | 0 (0) | 6 (8.1) | 0 (0) | 4 (7.1) | 0 (0) | 10 (7.7) | |||
| β-catenin | 0.009b | 0.433 | 0.073 | ||||||
| Negative | 4 (36.4) | 57 (77.0) | 4 (80.0) | 36 (64.3) | 8 (50.0) | 93 (71.5) | |||
| Positive | 7 (63.6) | 17 (23.0) | 1 (20.0) | 20 (35.7) | 8 (50.0) | 37 (28.5) | |||
| GS | 0.000b | 0.393 | 0.001b | ||||||
| Negative | 3 (27.3) | 62 (83.8) | 3 (60.0) | 42 (75.0) | 6 (37.5) | 104 (80.0) | |||
| Positive | 8 (72.7) | 12 (16.2) | 2 (40.0) | 14 (25.0) | 10 (62.5) | 26 (20.0) | |||
| SAA | 0.268 | 0.918 | 0.301 | ||||||
| Negative | 11 (100) | 65 (87.8) | 5 (100) | 55 (98.2) | 16 (100) | 120 (92.3) | |||
| Positive | 0 (0) | 9 (12.2) | 0 (0) | 1 (1.8) | 0 (0) | 10 (7.7) | |||
b
P < 0.01, L-FABP-negative small HCCs vs L-FABP-positive small HCCs. L-FABP: Liver fatty acid-binding protein; CK: Cytokeratin; GS: Glutamine synthetase; SAA: Serum amyloid A; HCC: Hepatocellular carcinoma.